drugset / Trial / NCT02242253

Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02242253

Phase 2 Completed 97 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Main Study: To evaluate and to compare the lung function response to the free combinations of tiotropium 18 μg (QD) + salmeterol 50 μg (QD or BID), salmeterol 50 μg BID and tiotropium 18 μg QD at the end of 6-week treatment periods in patients with COPD. Sub-Study: Was performed in subset of patients participating in the Main Study to assess the effect of the four randomised treatments on dynamic hyperinflation. Extension Study: To establish whether the FEV1 time profile following combination bronchodilator therapy of tiotropium plus salmeterol is affected by the pharmaceutical formulation of salmeterol, i.e. the MDI or the Diskus®.

Timeline

Start
2003-09
Primary completion
2004-07
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Salmeterol Other / unclassified 50 ug Inhaled
Subject Tiotropium Other / unclassified 18 ug Inhaled